Menu

Source Legend
  • Human-provided

    Entered or confirmed by an authorized person.

  • Google

    Imported Google information.

  • Trial-derived

    Calculated or extracted directly from associated trial records.

  • AI-inferred

    A capability inferred from trial history.

  • AI-extracted

    An explicit statement extracted from an official source.

  • Public registry

    Information from a public registry.

  • Site record

    Information held in the site record.

Source: Site record. Institute Oncology Veneto

Claim This Site

Are you the site administrator? Claim this site to update information.

Basic Information

Site Overview

Source: Human-provided.

The Istituto Oncologico Veneto (IOV) - IRCCS, located at Via Gattamelata, 64 in Padova, Italy, serves as a premier national center of excellence and a Comprehensive Cancer Centre dedicated to prevention, diagnosis, treatment, and biomedical research. Operating in close association with the University of Padua, the institute functions as the primary coordination hub for the Veneto Oncology Network.

Business Status

Source: Human-provided. OPEN

Business Category

Source: Human-provided. Cancer treatment center

Business Subcategory

Source: Human-provided. Cancer treatment center
Source: Human-provided. Oncologist
Source: Trial-derived.
127Total Trials
Source: Trial-derived.
28Recruiting Trials
Source: Trial-derived.
73Active Trials
Source: Trial-derived.
40Completed Trials
Source: Trial-derived.
174Unique Conditions
Source: Trial-derived.
140Unique Sponsors

Conditions

Source: Trial-derived. Melanoma (8)Source: Trial-derived. Breast Cancer (7)Source: Trial-derived. Non Small Cell Lung Cancer (5)Source: Trial-derived. Ovarian Cancer (5)Source: Trial-derived. Gastric Cancer (4)Source: Trial-derived. Metastatic Colorectal Cancer (4)Source: Trial-derived. Cholangiocarcinoma (3)Source: Trial-derived. Elderly Metastatic Colorectal Cancer Patients (3)

Sponsors

Source: Trial-derived. European Organisation for Research and Treatment of Cancer - EORTC (7)Source: Trial-derived. Fondazione Italiana Linfomi - ETS (7)Source: Trial-derived. Incyte Corporation (7)Source: Trial-derived. Merck Sharp & Dohme LLC (7)Source: Trial-derived. AstraZeneca (6)Source: Trial-derived. Bristol-Myers Squibb (6)Source: Trial-derived. Gruppo Oncologico del Nord-Ovest (6)Source: Trial-derived. Daiichi Sankyo (5)

Research Technology

Research technology inferred from trial participation

Source: AI-inferred. Electronic data capture

Imaging & Diagnostics

Imaging and diagnostic capabilities inferred from trial participation

Source: AI-inferred. Electrocardiography (lead count not stated)
Source: AI-inferred. CT Scan
Source: AI-inferred. MRI
Source: AI-inferred. 12-lead ECG
Source: AI-inferred. Echocardiography
Source: AI-inferred. Ultrasound

Laboratory & Biospecimens

Laboratory and biospecimen capabilities inferred from trial participation

Source: AI-inferred. Clinical laboratory testing
Source: AI-inferred. Timed pharmacokinetic sampling and processing
Source: AI-inferred. Histology / pathology
Source: AI-inferred. PCR / molecular
Source: AI-inferred. Specimen packaging and shipment
Source: AI-inferred. Clinical microbiology culture
Source: AI-inferred. Sequencing / genomics

Research Pharmacy & Investigational Product

Investigational-product capabilities inferred from trial participation

Source: AI-inferred. Hazardous / cytotoxic drug handling
Source: AI-inferred. Sterile preparation (laminar-flow hood / BSC or cleanroom)

Clinical Procedures

Clinical procedures inferred from trial participation

Source: AI-inferred. Intravenous infusion administration
Source: AI-inferred. Surgery / operating room
Source: AI-inferred. Image-guided thermal tumour ablation
Source: AI-inferred. Radiation therapy

Accessibility & Parking

Accessibility Features

Source: Google. Wheelchair accessible entrance
Source: Google. Wheelchair accessible parking lot
Source: Google. Wheelchair accessible restroom

Amenities

Amenities Available

Source: Google. Restroom

Additional Capabilities

Other capabilities inferred from trial participation

Source: AI-inferred. Ophthalmologic examination
Source: AI-inferred. Tumour PD-L1 expression testing
Source: AI-inferred. Tumour PD-L1 testing
Source: AI-inferred. BRAF mutation testing
Source: AI-inferred. Cytokine testing
Source: AI-inferred. EGFR mutation and ALK rearrangement testing
Source: AI-inferred. Electronic patient-reported outcome collection
Source: AI-inferred. FGFR genetic aberration testing